On January 29, Shenzhen Huada Gene Co., Ltd. released its 2017 annual results forecast. 2017 profit: 3.8 million yuan – 439 million yuan, profit for the same period of 2016: 332,690,900 yuan, an increase over the same period of the previous year: 14.22% - 29.25%.
Shenzhen Huada Gene Co., Ltd. released the 2017 annual results forecast. 2017 profit: 3.8 million yuan – 439 million yuan, profit for the same period of 2016: 332,690,900 yuan, an increase over the same period of the previous year: 14.22% - 29.25%.
Performance growth description:
1. During the reporting period, the company's various businesses continued to grow in the first half of the year. Reproductive health, basic research, complex diseases and drug research and development continued to grow compared with the same period last year. It is expected that the net profit attributable to shareholders of listed companies will increase from 14.22% to 29.25% from the same period of the previous year.
2. It is estimated that the company's non-recurring gains and losses attributable to shareholders of listed companies in 2017 will be approximately RMB 78 million (mainly interest income from wealth management products, government subsidy income, etc.), which is about RMB 17 million lower than the same period of last year, mainly due to the same period last year. The equity of the associate company generated an investment income of approximately RMB 11 million and the interest income of wealth management products decreased.
Performance growth description:
1. During the reporting period, the company's various businesses continued to grow in the first half of the year. Reproductive health, basic research, complex diseases and drug research and development continued to grow compared with the same period last year. It is expected that the net profit attributable to shareholders of listed companies will increase from 14.22% to 29.25% from the same period of the previous year.
2. It is estimated that the company's non-recurring gains and losses attributable to shareholders of listed companies in 2017 will be approximately RMB 78 million (mainly interest income from wealth management products, government subsidy income, etc.), which is about RMB 17 million lower than the same period of last year, mainly due to the same period last year. The equity of the associate company generated an investment income of approximately RMB 11 million and the interest income of wealth management products decreased.
Eye Massage,Best Eye Massager,Eye Care Massager,Eye Roller Massager
Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizon.com